Project AMLSG 20-13

Basic data

Title:
AMLSG 20-13
Duration:
01/03/2016 to 30/06/2021
Abstract / short description:
Dose Finding Safety Runiin Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Internal Medicine Department II
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Ulm, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.